Located on the University of Wyoming campus and anchored in technology licensed from the University and undertaken by the firm's founder, GlycoBac to structured around use of genetically engineered insect cells for manufacturing vaccines, diagnostics or therapeutics for use in human and veterinary medicine. GlycoBac LLC, is working on new, genetically engineered, insect cell lines optimized for this purpose.Those lines will then be broadly offered throughout the biotechnology community as a new biologics manufacturing platform. Biologics are a class of protein-based drugs that include vaccines, diagnostic testing reagents, and therapeutics, such as high-value cancer-fighting antibodies and proteins that can be used to treat genetic diseases, including diabetes and anemia. In late 2018, GlycoBac LLC,, and MilliporeSigma - a multinational conglomerate and subsidiary company to Merck KGaA, based in Darmstadt, Germany - recently partnered to offer a rhabdovirus-free insect platform for viral vaccines and gene therapy development.
